Sera Prognostics, Inc. (NASDAQ:SERA) General Counsel Benjamin Jackson Sells 7,912 Shares

Sera Prognostics, Inc. (NASDAQ:SERA) General Counsel Benjamin Jackson sold 7,912 shares of the firm’s stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $6.38, for a total value of $50,478.56. Following the completion of the transaction, the general counsel now directly owns 120,561 shares in the company, valued at $769,179.18. This trade represents a 6.16 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Benjamin Jackson also recently made the following trade(s):

• On Friday, January 10th, Benjamin Jackson sold 13,272 shares of Sera Prognostics stock. The shares were sold at an average price of $7.42, for a total value of $98,478.24.
• On Monday, November 11th, Benjamin Jackson sold 4,727 shares of Sera Prognostics stock. The stock was sold at an average price of $7.32, for a total transaction of $34,601.64.

Sera Prognostics Price Performance

SERA opened at $6.37 on Wednesday. The company has a 50 day simple moving average of $7.44 and a two-hundred day simple moving average of $7.31. The firm has a market cap of $215.13 million, a P/E ratio of -6.43 and a beta of 0.86. Sera Prognostics, Inc. has a 1-year low of $4.98 and a 1-year high of $12.35.

Sera Prognostics (NASDAQ:SERA) last released its earnings results on Wednesday, November 6th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.02). The company had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.09 million. During the same quarter last year, the business posted ($0.23) EPS. Equities analysts anticipate that Sera Prognostics, Inc. will post -0.96 earnings per share for the current year.

Hedge Funds Weigh In On Sera Prognostics

A number of hedge funds have recently made changes to their positions in SERA. Quest Partners LLC raised its stake in Sera Prognostics by 533.5% during the 3rd quarter. Quest Partners LLC now owns 6,430 shares of the company’s stock valued at $50,000 after purchasing an additional 5,415 shares during the period. The Manufacturers Life Insurance Company bought a new stake in shares of Sera Prognostics during the second quarter valued at approximately $68,000. SG Americas Securities LLC purchased a new position in shares of Sera Prognostics in the third quarter worth $78,000. Prime Capital Investment Advisors LLC bought a new position in shares of Sera Prognostics during the third quarter worth $104,000. Finally, Jane Street Group LLC boosted its position in shares of Sera Prognostics by 24.8% during the third quarter. Jane Street Group LLC now owns 14,225 shares of the company’s stock worth $111,000 after acquiring an additional 2,826 shares during the last quarter. Institutional investors own 54.64% of the company’s stock.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.